PE20121520A1 - Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular - Google Patents

Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular

Info

Publication number
PE20121520A1
PE20121520A1 PE2012000852A PE2012000852A PE20121520A1 PE 20121520 A1 PE20121520 A1 PE 20121520A1 PE 2012000852 A PE2012000852 A PE 2012000852A PE 2012000852 A PE2012000852 A PE 2012000852A PE 20121520 A1 PE20121520 A1 PE 20121520A1
Authority
PE
Peru
Prior art keywords
dronedarone
treatment
pharmaceutical formulation
atrial fibrillation
ranolazine
Prior art date
Application number
PE2012000852A
Other languages
English (en)
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20121520A1 publication Critical patent/PE20121520A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA QUE CONTIENE: A) RANOLAZINA EN UNA CANTIDAD DE 50MG A 1000MG, Y B) DRONEDARONA EN UNA CANTIDAD DE 10MG A 800MG; EN DONDE AMBOS COMPUESTOS SE ENCUENTRAN EN CANTIDADES SINERGICAMENTE TERAPEUTICAS Y SU COADMINISTRACION REDUCE LOS EFECTOS SECUNDARIOS NO DESEADOS DE DRONEDARONA Y REDUCE LA PROLONGACION DEL INTERVALO QT EN UN PACIENTE PROVOCADA POR RANOLAZINA. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE FIBRILACION AURICULAR O ALETEO AURICULAR
PE2012000852A 2009-12-21 2010-12-20 Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular PE20121520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
PE20121520A1 true PE20121520A1 (es) 2012-11-26

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000852A PE20121520A1 (es) 2009-12-21 2010-12-20 Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular

Country Status (37)

Country Link
US (3) US8513254B2 (es)
EP (2) EP2515900B1 (es)
JP (2) JP5723889B2 (es)
KR (2) KR20120107995A (es)
CN (3) CN104688739A (es)
AP (1) AP3536A (es)
AR (1) AR079552A1 (es)
AU (1) AU2010339753B2 (es)
BR (1) BR112012015499A2 (es)
CA (1) CA2784028C (es)
CL (1) CL2012001597A1 (es)
CR (1) CR20120353A (es)
CY (1) CY1116511T1 (es)
DK (1) DK2515900T3 (es)
EA (2) EA201691336A1 (es)
EC (1) ECSP12012004A (es)
ES (2) ES2540093T3 (es)
HK (1) HK1170675A1 (es)
HR (1) HRP20150644T1 (es)
HU (1) HUE026916T2 (es)
IL (1) IL220152A (es)
ME (1) ME02179B (es)
MX (2) MX2012007052A (es)
NO (1) NO2749282T3 (es)
NZ (2) NZ627181A (es)
PE (1) PE20121520A1 (es)
PL (2) PL2515900T3 (es)
PT (2) PT2749282T (es)
RS (1) RS54118B1 (es)
SG (3) SG181541A1 (es)
SI (2) SI2515900T1 (es)
SM (1) SMT201500171B (es)
TW (1) TWI508726B (es)
UA (1) UA109887C2 (es)
UY (1) UY33119A (es)
WO (1) WO2011084733A1 (es)
ZA (1) ZA201204608B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332540A1 (en) 2002-05-21 2011-06-15 Cv Therapeutics, Inc. Administration of ranolazine for the treatment of diabetes
ES2642586T3 (es) * 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
EP3760180A3 (en) 2009-07-29 2021-01-20 ICU Medical, Inc. Fluid transfer devices and methods of use
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NZ627942A (en) * 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
MX2016001303A (es) * 2013-08-02 2016-04-07 Gilead Sciences Inc Composiciones farmaceuticas de ranolazina y dronedarona.
US9932588B2 (en) * 2013-11-15 2018-04-03 Northwestern University Inhibition of oxidative stress in atrial fibrillation
AU2014364783B2 (en) 2013-12-19 2017-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
CN113993551A (zh) * 2019-01-24 2022-01-28 西北大学 心房颤动的基因疗法治疗

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE223218T1 (de) 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
ES2281431T3 (es) * 2000-07-27 2007-10-01 Pharmacia Corporation Terapia de combinacion con antagonista epoxi-esteroidal de aldosterona y bloqueador de los canales de calcio para tratamiento de la insuficiencia cardiaca congestiva.
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
US7022343B2 (en) 2000-12-27 2006-04-04 Genzyme Corporation Controlled release of anti-arrhythmic agents
US20050065208A1 (en) * 2001-07-20 2005-03-24 Bodo Brandts Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
CN101098682A (zh) 2005-01-06 2008-01-02 Cv医药有限公司 包括雷诺嗪的缓释药物制剂
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法

Also Published As

Publication number Publication date
SG10201710751TA (en) 2018-02-27
ECSP12012004A (es) 2012-08-31
US20110183990A1 (en) 2011-07-28
AR079552A1 (es) 2012-02-01
KR20120107995A (ko) 2012-10-04
NO2749282T3 (es) 2018-01-06
ME02179B (me) 2015-10-20
NZ627181A (en) 2016-02-26
US20140323493A1 (en) 2014-10-30
PL2515900T3 (pl) 2015-10-30
ES2540093T3 (es) 2015-07-08
UA109887C2 (uk) 2015-10-26
SMT201500171B (it) 2015-09-07
US8754087B2 (en) 2014-06-17
CN102665713B (zh) 2015-02-18
ZA201204608B (en) 2013-02-27
MX344329B (es) 2016-12-13
NZ600718A (en) 2014-08-29
EP2749282A1 (en) 2014-07-02
TW201136586A (en) 2011-11-01
PL2749282T3 (pl) 2018-01-31
CR20120353A (es) 2014-10-07
EP2749282B1 (en) 2017-08-09
AU2010339753A1 (en) 2012-07-12
SG181541A1 (en) 2012-07-30
CA2784028C (en) 2016-08-23
AU2010339753B2 (en) 2015-01-22
SI2515900T1 (sl) 2015-07-31
AP2012006331A0 (en) 2012-06-30
EA201290451A1 (ru) 2013-01-30
JP2015057449A (ja) 2015-03-26
US9056108B2 (en) 2015-06-16
AP3536A (en) 2016-01-13
HUE026916T2 (en) 2016-08-29
CN102665713A (zh) 2012-09-12
IL220152A0 (en) 2012-07-31
CA2784028A1 (en) 2011-07-14
UY33119A (es) 2011-07-29
CN104688739A (zh) 2015-06-10
DK2515900T3 (en) 2015-07-27
US20130317038A1 (en) 2013-11-28
ES2646603T3 (es) 2017-12-14
EA201691336A1 (ru) 2017-05-31
MX2012007052A (es) 2012-07-30
JP2013515007A (ja) 2013-05-02
US8513254B2 (en) 2013-08-20
KR20160108611A (ko) 2016-09-19
SI2749282T1 (sl) 2017-12-29
EP2515900A1 (en) 2012-10-31
EA025445B1 (ru) 2016-12-30
PT2749282T (pt) 2017-11-15
RS54118B1 (en) 2015-12-31
JP5723889B2 (ja) 2015-05-27
CL2012001597A1 (es) 2013-06-28
TWI508726B (zh) 2015-11-21
IL220152A (en) 2016-11-30
WO2011084733A1 (en) 2011-07-14
PT2515900E (pt) 2015-07-30
HK1170675A1 (en) 2013-03-08
BR112012015499A2 (pt) 2016-05-03
HRP20150644T1 (hr) 2015-07-31
EP2515900B1 (en) 2015-04-29
CN104147010A (zh) 2014-11-19
CY1116511T1 (el) 2017-03-15
SG10201408528RA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
BR112012023021A2 (pt) compostos de indazol e seus usos
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
ECSP10010589A (es) Farmaco contra el cancer de higado
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
CR20140086A (es) Tratamientos de combinación para hepatitis c
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
UY31228A1 (es) Ariloxazoles sustituidos y su uso
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
NI201200196A (es) Agentes terapéuticos 976

Legal Events

Date Code Title Description
FG Grant, registration